01455nas a2200193   4500008004100000245005800041210005600099260001500155300000900170490000600179520092000185653002601105653001301131653001201144653002001156653001701176100002301193856004501216       2014                        eng d00aSaroglitazar: India's Answer to Diabetic Dyslipidemia0 aSaroglitazar Indias Answer to Diabetic Dyslipidemia  cMarch 2014  a7-140 v33 a<p class="rtejustify">Incidence of dyslipidemia among people suffering from diabetes is shooting up each year around the globe. A novel target to control this disorder has agonistic activity on peroxisome proliferator-activated receptors (PPAR)-α and PPAR-γ receptors simultaneously. While the α form has lipid lowering effects, γ leads to lowering in blood glucose. Saroglitazar (Lipaglyn), developed by Zydus Cadila, first new chemical entity (NCE) discovered and developed indige-nously by an Indian Pharma Company, has agonistic activity on both PPAR-α and PPAR-γ receptors. Unlike other glitazars that were discontinued during their development, saroglitazar enjoys a high benefit-to-risk ratio. It is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes mellitus not controlled by conventional therapy. Dose recommended for Lipaglyn is 4mg once a day.</p>
10aDiabetic dyslipidemia10aGlitazar10aPPAR-α10aPPAR-γ agonist10aSaroglitazar1 aAggarwal, Akanksha  uhttps://www.ijphs.org/article/2014/3/1-0